PHARMAC is interested in receiving information from suppliers, clinicians and diabetes healthcare professionals in respect of the following classes of anti-diabetic agents:

a. dipeptidyl peptidase4 inhibitors (DPP4-inhibitors)

b. glucagon-like peptide-1 agonists (GLP-1s)

c. sodium glucose co-transporter 2 inhibitors (SGLT-2s)

d. combination anti-diabetic agents (e.g. DPP4-inhibitors/metformin)

The purpose of this request for information (RFI) is to seek information to inform and assist PHARMAC in determining the most appropriate funding arrangement and process, which may include progressing to a request for proposals (RFP) or other competitive process at a later date.

For more details, go to: http://www.pharmac.health.nz/news/rfi-2015-02-12-anti-diabetic-agents/